TABLE 1.
Clinical feature of the participants in the cohort
| Variable |
Breast cancer patients (n = 60) |
Control (n = 32) |
p |
|---|---|---|---|
| Age | |||
| ≤45 years | 17 (28.3%) | 6 (18.8%) | >0.05 a |
| >45 years | 43 (71.7%) | 26 (81.3%) | |
| Gender | |||
| Female | 60 (100%) | 32 (100%) | — |
| Tumor size (maximum diameter) | |||
| ≥3 cm | 17 (28.3%) | >0.05 b | |
| <3 cm | 43 (71.7%) | ||
| Metastasis status | |||
| Yes | 8 (13.3%) | <0.05 b | |
| No | 52 (86.7%) | ||
| TNM stage | |||
| Ⅰ | 17 (28.3%) | >0.05 b | |
| Ⅱ | 17 (28.3%) | ||
| Ⅲ | 18 (30.0%) | ||
| Ⅳ | 8 (13.3%) | ||
| CEA | 1.58 ± 2.04 | 0.87 ± 0.55 | >0.05 a |
| CA125 | 14.25 ± 14.82 | 7.91 ± 3.11 | >0.05 a |
| CA153 | 12.87 ± 16.00 | 5.61 ± 4.83 | <0.05 a |
Abbreviations: CA125, carbohydrate antigen 125; CA153, carbohydrate antigen 153; CEA, carcinoembryonic antigen.
a
Denoted the statistical difference between the breast cancer patients and the control group.
b
Denoted the differences among the subgroups in the breast cancer patients.